The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseasesHOUSTON, April 22, ...

Stem cells are often described as the body's master cells. Healthy stem cells can restore the blood system after cancer ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to ...

Out of curiosity she plugged her collection of symptoms into the artificial intelligence chatbot, Chat GPT. To her surprise, ...

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly ...

Tina Knowles reflected on finding out she had stage 1 breast cancer and subsequently undergoing surgery: "I was in disbelief." ...